Expert Insight: Upcoming Webinar: Label-Free Techniques for Drug Discovery – Utilizing SPR and MALDI Mass Spectrometry for High-Throughput Screening

Dr. Meike Hamester, Director of Small Molecule Pharma Business at Bruker Daltonik, and Sven Malik, Senior Application Specialist at Bruker

---

An upcoming SelectScience^® webinar will explore the latest developments in MALDI mass spectrometry for high-throughput screening and CPD profiling (rapifleX MALDI PharmaPulse) and introduce Bruker's new surface plasmon resonance (SPR) instrument, the SIERRA SPR-32. Beside technical details explaining the latest developments, synergies between MALDI mass spectrometry and SPR will be discussed.

In this webinar, presented by Meike Hamester and Sven Malik, you will learn about:

• Primary and secondary screening in drug discovery
• Label-free technologies to reduce artefacts / importance of controls in SPR experiments
• Kinetic characterization: Determination of KDon- and KDoff-rates of compounds (SPR)
• Automation strategies to maximize throughput (SPR and MALDI)

Now working for Bruker Daltonik and Bruker as director of small molecule business and applications specialist respectively, the speakers offer a combined 25 years of specialism in SPR and mass spectrometry between them. 

Who should attend?

• Drug discovery laboratories
• Research staff
• Pharmaceutical companies

All webinar participants can request a certificate of attendance, with a learning outcomes summary document, for continuing education purposes.

Attend the live webinar on Monday, August 13, at:

• 16:00 BST
• 17:00 CEST
• 11:00 EDT
• 08:00 PDT

If you can’t attend the live event, register to watch the webinar on demand at a time that suits you.